Galapagos NV: First patients screened for Phase 2B studies

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Galapagos NV: First patients screened for Phase 2B studies with GLPG0634

MECHELEN, BELGIUM--(Marketwired - Jul 1, 2013) -

* First rheumatoid arthritis patients screened in Belgium

* Galapagos on track with DARWIN Phase 2B program in rheumatoid arthritis

* 875 patients to be enrolled worldwide for 24 weeks of treatment

* Topline 12-week data from DARWIN 1 and DARWIN 2 available by end 2014

Galapagos NV ( EURONEXT BRUSSELS : GLPG ) announced today that the first rheumatoid arthritis (RA) patients have been screened for enrolment in the Phase 2B clinical program with GLPG0634, a selective JAK1 inhibitor. The DARWIN Phase 2B program includes two dose finding studies and an open label extension study. The dose finding studies will evaluate the efficacy and safety of GLPG0634 with 24 weeks of treatment in 875 moderate to severe RA patients refractory to methotrexate.

GLPG0634 is the first selective JAK1 inhibitor in development for RA. The results of two 4-week Phase 2A clinical studies demonstrated the rapid clinical benefit and favorable safety profile of the drug, and supported the selection of the GLPG0634 doses that will be evaluated in the current Phase 2B program. Galapagos started the 24-week global DARWIN Phase 2B program in RA to identify the dose and dose-regimen that offers optimal efficacy and safety of GLPG0634 in patients with moderate to severe RA. Galapagos expects to report completion of recruitment by mid-2014 and 12-week topline data from the Phase 2B program in Q4 2014.

"GLPG0634 has shown a rapid suppression of disease activity with a good safety profile in the 4-week Phase 2A studies in RA patients. We look forward to seeing the effect of GLPG0634 in a global study, for a longer treatment period, and in a larger and more diverse patient population. The first patients will be recruited in Belgium and New Zealand," said Dr Piet Wigerinck, Chief Scientific Officer of Galapagos. "Galapagos is on track in the RA program and is now also preparing for a Phase 2 study with GLPG0634 in Crohn's disease, which will run in parallel with the Phase 2B study in RA. By early 2014, we will have Phase 2 programs with GLPG0634 in RA and Crohn's, both with final readouts before mid-2015."

Details of the DARWIN Phase 2B program

The Phase 2B program, named DARWIN (Drug Against Rheumatoid Arthritis With Selective JAK1 INhibition) includes 2 dose finding studies, DARWIN 1 and DARWIN 2, and an open label extension study, DARWIN 3. All patients will have received methotrexate (MTX) but no longer have an adequate therapeutic response to this first-line therapy in RA. Patients will not have been exposed to prior biological treatments.

DARWIN 1 will enroll 595 patients who will continue their stable therapy of MTX while receiving GLPG0634 or placebo, whereas in DARWIN 2, 280 patients will stop MTX and receive monotherapy of GLPG0634 or placebo. All patients who receive placebo or low dose GLPG0634 and do not show improvement after 12 weeks of treatment will be randomized to a higher dose of GLPG0634. After completion of 24 weeks in either DARWIN 1 or 2, patients may continue open-label GLPG0634 as part of DARWIN 3, an extension study that will collect long-term safety and efficacy data.

GLPG0634 doses in DARWIN 1 and 2 will be 50, 100 and 200 mg per day. In DARWIN 1, these doses will be given as once-daily and twice-daily regimens (daily doses split in two), whereas only once-daily dosing will be evaluated in DARWIN 2. The DARWIN program will recruit patients from Europe, the Americas, Australia, and New-Zealand.

About candidate drug GLPG0634

GLPG0634 is an orally-available, novel Janus kinase (JAK) inhibitor with selectivity for JAK1 developed by Galapagos. JAKs are critical components of signalling mechanisms utilized by a number of cytokines and growth factors, including those that are elevated in rheumatoid arthritis patients. JAK inhibitors have shown long-term efficacy in rheumatoid arthritis studies with an early onset of action. GLPG0634 differentiates from other JAK inhibitors in development by specifically targeting JAK1, a strategy which could result in a better efficacy and safety profile. GLPG0634 is a fully proprietary program. Upon successful completion of the Phase 2B studies in RA, AbbVie will license the program and will assume sole responsibility for Phase 3 clinical development and global manufacturing.

About Galapagos

Galapagos ( EURONEXT BRUSSELS : GLPG ) ( PINKSHEETS : GLPYY ) is specialized in novel modes-of-action, with a large pipeline of four clinical, seven pre-clinical, and 30 discovery small-molecule and antibody programs in cystic fibrosis, inflammation, antibiotics, metabolic disease, and other indications. GLPG0634 is an orally-available, selective inhibitor of JAK1 for the treatment of rheumatoid arthritis and potentially other inflammatory diseases, currently in Phase 2B studies in RA and about to enter Phase 2 studies in Crohn's disease. AbbVie and Galapagos signed a worldwide license agreement whereby AbbVie will be responsible for further development and commercialization after Phase 2B. Galapagos has another selective JAK1 inhibitor in Phase 2 in lupus and psoriasis, GSK2586184 (formerly GLPG0778, in-licensed by GlaxoSmithKline in 2012). GLPG0187 is a novel integrin receptor antagonist currently in a Phase 1B patient study in metastasis. GLPG0974 is the first inhibitor of FFA2 to be evaluated clinically for the treatment of IBD; this program is currently in a Proof of Concept Phase 2 study. The Galapagos Group, including fee-for-service companies BioFocus, Argenta and Fidelta, has 800 employees and operates facilities in five countries, with global headquarters in Mechelen, Belgium. Further information at: www.glpg.com

This release may contain forward-looking statements, including, without limitation, statements containing the words "believes," "anticipates," "expects," "intends," "plans," "seeks," "estimates," "may," "will," "could," "stands to," and "continues," as well as similar expressions. Such forward-looking statements may involve known and unknown risks, uncertainties and other factors which might cause the actual results, financial condition, performance or achievements of Galapagos, or industry results, to be materially different from any historic or future results, financial conditions, performance or achievements expressed or implied by such forward-looking statements. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. Galapagos expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless required by law or regulation.

First patients screened for Phase 2B studies with GLPG0634: http://hugin.info/133350/R/1712941/568497.pdf

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Galapagos NV via Thomson Reuters ONE

[HUG#1712941]

CONTACT Galapagos NV Piet Wigerinck SVP Development Tel: +32 477 62 7103 Elizabeth Goodwin Director Investor Relations Tel: +31 6 2291 6240 Email Contact

Scroll down for more posts ▼

Top 10 Most Recent News Articles

AdMaven's Mave AI: Revolutionizing Campaign Management

Updated Category News Views 106

Taking the Tedious Out of Advertising You've got to love it when technology actually makes life easier, rather than more complicated. AdMaven's latest fancy toy, the AI assistant Mave, is promising just that. It's designed to take the heavy lifting off advertisers' shoulders, especially the day-to-day grind of tweaking ad settings and monitoring performance. If you've...

Continue Reading
Loyalty Programs Cut $1500 Annually for Consumers

Updated Category News Views 56

Loyalty Programs: An Essential Tool for Households In a world where every dollar counts, retail loyalty programs have become more than just a marketing strategy—they're lifelines for American households scraping through each month. According to fresh research by the Retail Industry Leaders Association (RILA) and conducted by market research leader Circana, these...

Continue Reading
Midea's R290 Tech: Real Green Cooling Revolution?

Updated Category News Views 258

A Fresh Breeze in Sustainable Cooling In the middle of Kigali’s innovation oasis, Midea RAC stood out at MOP38, the 38th Meeting of the Parties to the Montreal Protocol, flexing its sustainable tech muscles. We're talking about their R290 air conditioning technology—a natural refrigerant with zero ozone footprint and a global warming potential of a mere three. This is...

Continue Reading
ROBOTERA Debuts XHAND 1 Pro-U in NVIDIA Demo

Updated Category News Views 145

ROBOTERA Steps Up with XHAND 1 Pro-U Move over, traditional robotics; ROBOTERA is here to shake things up with their latest marvel, the XHAND 1 Pro-U. This futuristic gadget isn't just making waves at the Conference on Robot Learning (CoRL) where Jim Fan of NVIDIA spotlighted it in his GR00T 2 demo, it's setting a new bar for robotic dexterity. Hand in Glove with Human...

Continue Reading
DarioHealth's New Research Tackles Healthcare Cost Estimation

Updated Category News Views 104

Unpacking Dario's Bold Surgical Strike at ISPOR Europe Alright, folks, DarioHealth is shaking up the stage with their new methodology that could very well carve a new path in how we size up digital healthcare savings. Presented at ISPOR Europe 2026, Dario's tactic bypasses the sluggish wait on medical claims data, instead offering an evidence-driven peek at potential...

Continue Reading
Alliance for Women in Media Champions Change in 2026

Updated Category News Views 60

A Celebration of Trailblazing Women in Media If there's one thing I've learned about strong leadership, it's that you can't fake authenticity. Today, we're tipping our hats to some genuine trailblazers. The Alliance for Women in Media (AWM) held its annual Gracies Leadership Awards, celebrating the achievements and vision of seven remarkable women. Honoring the...

Continue Reading
Lennar Faces Legal Heat Over Alleged Misleading Statements

Updated Category News Views 39

Rumbling Legal Drama with Lennar Corporation Every trader knows the uneasy feeling when a stock you're eyeing takes a surprising nosedive on some legal muck coming out of the woodwork. Well, it's Lennar Corporation's turn in the spotlight for all the wrong reasons. They're getting slapped with a class action lawsuit by investors claiming the company pulled a fast one...

Continue Reading
Caladan Partners with Anchorage for Stronger Trading

Updated Category News Views 50

Caladan and Anchorage Unite for Asset Growth Man, partnerships might just be the secret sauce we never know we need until it’s on our plate. It's a fresh day in digital trading, and Caladan just shook things up by teaming up with Anchorage Digital, bolstering their trading and settlement capabilities to satisfy the big players. If there's one thing that's hot as a...

Continue Reading
Thunes Boosts Bhutan Remittances with Instant Payments

Updated Category News Views 283

Thunes' Network Expands to Bhutan: A Game Changer I'll say one thing clear—Thunes isn't messing around. They've just opened the gates for real-time payouts to Bhutan, and it's going to be a game-changer for those living abroad who want to send money back home. Look, for years, Non-Resident Bhutanese have been diving into hoops just to get their bucks across borders....

Continue Reading
Dr. Obeng Joins WellcomeMD with Special Offer for Patients

Updated Category News Views 23

New Beginnings in Concierge Medicine In late October, WellcomeMD opened its doors to Dr. Paa-Kofi Obeng—an arrival greeted with considerable anticipation in Richmond's medical scene. This isn't just any run-of-the-mill staff addition; Dr. Obeng brings with him over a decade of experience from places like the Veterans Administration Medical Center. He's armed with a...

Continue Reading

Top 5 Most Recently Viewed Articles

Analysts Alter Predictions for Texas Instruments Earnings Release

Updated Category News Views 48

Analysts Update Forecasts for Texas Instruments Earnings Texas Instruments Incorporated (NASDAQ: TXN) is set to unveil its third-quarter earnings results, scheduled for release after the market closes on a Tuesday evening. Investors are keenly anticipating the outcome as industry buzz suggests that earnings could reflect a notable change from previous figures. Current...

Continue Reading
Iris Energy Limited: Understanding Investor Rights and Legal Options

Updated Category News Views 117

Understanding Your Rights as an Investor in Iris Energy Limited As an investor in Iris Energy Limited, it’s essential to know your rights, especially during challenging times. The legal landscape surrounding securities can be complex, and having informed legal support is crucial. Many investors are unaware of their options and the potential to recover losses stemming...

Continue Reading
McKesson Corporation Set to Release Earnings This November

Updated Category News Views 108

McKesson Corporation's Second Quarter Earnings Announcement McKesson Corporation (NYSE: MCK) is preparing to release its earnings report for the second quarter of fiscal 2025, which will happen after the market closes. Investors and stakeholders can expect to see the detailed financial results made public on a Wednesday. This announcement is a significant moment for the...

Continue Reading
Advantech's Innovations at Medical AI Solutions Conference

Updated Category News Views 122

Advantech Unveils Cutting-Edge Medical AI Solutions Advantech, a renowned global leader in industrial IoT and edge computing solutions, is excited to announce its presence at the MedTech Conference, an event that gathers leading figures in healthcare technology to discuss innovations shaping the future of patient care. Attendees will find Advantech at Booth #1007,...

Continue Reading
Canada's Defence Investment Spurs Innovation and Growth for Draganfly

Updated Category News Views 236

Canada's Defence Investment: A New Era for Technological Advancement In a bold effort to enhance national security, the Canadian government has revealed a significant long-term defence investment package worth $80 billion. This strategic move, championed by Prime Minister Mark Carney, is designed to advance technological capabilities in defence, bolster domestic...

Continue Reading